Jazz Pharmaceuticals PLC (JAZZ) Position Decreased by Nomura Holdings Inc.

Nomura Holdings Inc. reduced its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 93.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,950 shares of the specialty pharmaceutical company’s stock after selling 97,927 shares during the period. Nomura Holdings Inc.’s holdings in Jazz Pharmaceuticals PLC were worth $1,081,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. US Bancorp DE lifted its position in shares of Jazz Pharmaceuticals PLC by 94.4% during the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 368 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Jazz Pharmaceuticals PLC by 43.0% during the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after purchasing an additional 295 shares in the last quarter. Gargoyle Investment Advisor L.L.C. bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $206,000. Janney Montgomery Scott LLC bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $211,000. Finally, Brighton Jones LLC bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $213,000. 87.82% of the stock is currently owned by institutional investors.

In other Jazz Pharmaceuticals PLC news, Director Paul L. Berns sold 662 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $142.37, for a total transaction of $94,248.94. Following the completion of the transaction, the director now owns 6,599 shares of the company’s stock, valued at $939,499.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $150.00, for a total value of $150,000.00. The disclosure for this sale can be found here. Insiders have sold 9,097 shares of company stock valued at $1,398,423 in the last three months. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.85 by ($0.13). The company had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the business posted $2.67 EPS.

ILLEGAL ACTIVITY WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Position Decreased by Nomura Holdings Inc.” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://ledgergazette.com/2017/10/18/jazz-pharmaceuticals-plc-jazz-position-decreased-by-nomura-holdings-inc.html.

A number of research analysts recently weighed in on the stock. Cowen and Company reissued an “outperform” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Wells Fargo & Company reissued an “outperform” rating and set a $177.00 price target (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. Piper Jaffray Companies reissued a “buy” rating and set a $177.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. BMO Capital Markets reissued a “buy” rating and set a $196.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, September 20th. Finally, Janney Montgomery Scott reissued a “buy” rating and set a $192.00 price target (up from $180.00) on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eighteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $179.79.

Jazz Pharmaceuticals PLC Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of ph

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. US Bancorp DE lifted its position in shares of Jazz Pharmaceuticals PLC by 94.4% during the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 368 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Jazz Pharmaceuticals PLC by 43.0% during the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after purchasing an additional 295 shares in the last quarter. Gargoyle Investment Advisor L.L.C. bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $206,000. Janney Montgomery Scott LLC bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $211,000. Finally, Brighton Jones LLC bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $213,000. 87.82% of the stock is currently owned by institutional investors.

In other Jazz Pharmaceuticals PLC news, Director Paul L. Berns sold 662 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $142.37, for a total transaction of $94,248.94. Following the completion of the transaction, the director now owns 6,599 shares of the company’s stock, valued at $939,499.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $150.00, for a total value of $150,000.00. The disclosure for this sale can be found here. Insiders have sold 9,097 shares of company stock valued at $1,398,423 in the last three months. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.85 by ($0.13). The company had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the business posted $2.67 EPS.

ILLEGAL ACTIVITY WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Position Decreased by Nomura Holdings Inc.” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://ledgergazette.com/2017/10/18/jazz-pharmaceuticals-plc-jazz-position-decreased-by-nomura-holdings-inc.html.

A number of research analysts recently weighed in on the stock. Cowen and Company reissued an “outperform” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Wells Fargo & Company reissued an “outperform” rating and set a $177.00 price target (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. Piper Jaffray Companies reissued a “buy” rating and set a $177.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. BMO Capital Markets reissued a “buy” rating and set a $196.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, September 20th. Finally, Janney Montgomery Scott reissued a “buy” rating and set a $192.00 price target (up from $180.00) on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eighteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $179.79.

Jazz Pharmaceuticals PLC Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply